Kenneth C. Anderson, MD, of Dana-Farber/Brigham and Women’s Cancer Center, discusses the incredible progress made in treating multiple myeloma, with nine therapeutic options approved in the past decade, two drugs approved this year, and a number of new options on the horizon.
Eric Jonasch, MD, of The University of Texas, MD Anderson Cancer Center, discusses the progress being made in kidney cancer treatment and the clinical trials that focused on sunitinib, sorafenib, and everolimus, among others.
Peter G. Shields, MD, of The Ohio State University Comprehensive Cancer Center and the James Cancer Hospital and Solove Research Institute, discusses the new NCCN Guidelines for helping patients with cancer to stop smoking. Counseling is a critical part of these new recommendations.
Samuel M. Silver, MD, PhD, of the University of Michigan Comprehensive Cancer Center, and Margaret A. Tempero, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discuss drugs developed for hematologic malignancies that have activity in pancreatic cancer, vaccines, neoadjuvant treatment, and the need to focus on activated RAS.
Although guidelines worldwide mandate fertility preservation for newly diagnosed patients within their reproductive window, most patients are still not referred or offered this option. Rebecca H. Johnson, MD, of Mary Bridge Children’s Hospital, explains the steps that need to be taken when counseling patients.
Axel Grothey, MD, of the Mayo Clinic Cancer Center, discusses how the NCCN Guidelines can help oncologists make strategic choices of the various agents available to treat metastatic colorectal cancer, individualizing patient care.
